Company: Sigilon Therapeutics
Job title: Chief Operating Officer
Devyn Smith is Chief Operating Officer for Sigilon Therapeutics, a biotech company. He is tasked with building out the strategy and operational elements for a portfolio of potential new medicines. Prior to Sigilon, Devyn was part of Pfizer’s Medicinal Sciences Division of R&D as Head of Business Operations & Strategy. The focus of this role was both day to day business operations of the division, as well insuring implementable strategies were developed. Prior to this Devyn was Head of Strategy for the Pharma therapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions. Before this role, Devyn was part of Pfizer’s Neusentis Research Unit in the UK as Chief Operating Officer responsible for strategy, operations and implementing key strategies. In addition, he supported the Pharma therapeutics Global Clinical Research Organization as the Chief Operating Officer.
Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products.
Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.
Live Presenter Q&A 2:25 pm
day: Day One
A Novel Long-Term Treatment for Hemophilia A Using Shielded Living Therapeutics 1:45 pm
• Shielded living therapeutics utilize a novel cell platform combined with a novel biomaterial platform to potentially provide long lasting therapy for patients • Pre-clinical data demonstrates both safety as well as efficacy in animal models • Therapeutic is poised to enter the clinic this yearRead more
day: Day One